Los puntos clave no están disponibles para este artículo en este momento.
Eighteen years ago, Seattle-based Sound Pharmaceuticals hired WuXi AppTec, a Chinese drug services firm, to make small quantities of an active ingredient for preclinical studies of its drug candidate for hearing loss. The relationship between the two companies strengthened over time, and WuXi now handles all of Sound's drug manufacturing—from preclinical to clinical stages. "WuXi has done a lot of projects for us," says Jonathan Kil, Sound's CEO and chief scientific officer. "They started with making kilo batches of our drug substance; now they make 100 kg for precommercial use." Kil became worried when he heard in January that Congress was considering a bill that could prevent companies like his from doing business with WuXi. The Biosecure Act, introduced in the House of Representatives, sought to stop US businesses that receive federal funds from working with WuXi and three Chinese genomics companies. It claims that the firms have ties to
Aayushi Pratap (Mon,) studied this question.